We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $11.7B
1-Year Est. Return 174.13%
This Fund
S&P 500
This Quarter Est. Return
-18.55%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$322M
AUM Growth
-$21.7M
Cap. Flow
+$84.8M
Cap. Flow %
26.36%
Top 10 Hldgs %
71.05%
Holding
50
New
17
Increased
16
Reduced
6
Closed
5

Top Buys

Rank Stock Value
1
LJPC
La Jolla Pharmaceutical Company
LJPC
+$25.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14.6M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.6M
4
ATRA icon
Atara Biotherapeutics
ATRA
+$12.8M
5
INCY icon
Incyte
INCY
+$12.1M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$10.6M
2
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$3.88M
3
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$3.5M
4
ARWR icon
Arrowhead Research
ARWR
+$2.91M
5
USO icon
United States Oil Fund
USO
+$2.53M

Sector Composition

Rank Sector Weight
1 Healthcare 96.11%
2 Miscellaneous 3.88%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$35.6B
$42.9M 13.32%
533,660
+122,644
+30% +$13.6M
INCY icon
2
Incyte
INCY
$25.7B
$33.5M 10.39%
303,212
+108,212
+55% +$12.1M
LJPC
3
DELISTED
La Jolla Pharmaceutical Company
LJPC
$30M 9.33%
1,080,331
+796,631
+281% +$25.1M
BCRX icon
4
BioCryst Pharmaceuticals
BCRX
$2.55B
$25.4M 7.89%
2,228,206
-33,155
-1% -$442K
KITE
5
DELISTED
Kite Pharma, Inc.
KITE
$20.9M 6.5%
375,476
-24,524
-6% -$1.54M
ACHN
6
DELISTED
Achillion Pharmaceuticals
ACHN
$17.9M 5.56%
2,589,818
+74,385
+3% +$606K
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$16.6M 5.16%
+482,069
New +$14.6M
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$16.5M 5.12%
2,005,238
+725,352
+57% +$8.38M
BLUE
9
DELISTED
bluebird bio
BLUE
$13M 4.03%
11,703
+3,597
+44% +$6.56M
ARWR icon
10
Arrowhead Research
ARWR
$12.2B
$12.1M 3.75%
2,097,185
-462,815
-18% -$2.91M
FPRX
11
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$11M 3.41%
713,954
+153,517
+27% +$3.3M
AGEN
12
Agenus
AGEN
$371M
$9.59M 2.98%
106,187
+1,591
+2% +$236K
ATRA icon
13
Atara Biotherapeutics
ATRA
$98M
$8.27M 2.57%
+10,520
New +$12.8M
CLDX icon
14
Celldex Therapeutics
CLDX
$3.12B
$7.58M 2.35%
47,915
+16,478
+52% +$4.66M
SSRG
15
DELISTED
SYMMETRY SURGICAL INC COMMON STK
SSRG
$7.19M 2.23%
807,442
+106,591
+15% +$916K
BMY icon
16
Bristol-Myers Squibb
BMY
$136B
$6.06M 1.88%
102,425
+4,971
+5% +$315K
CORI
17
DELISTED
Corium International, Inc.
CORI
$5.38M 1.67%
575,212
+220,205
+62% +$2.64M
OMER icon
18
Omeros
OMER
$1.37B
$5.37M 1.67%
+490,000
New +$7.63M
RGNX icon
19
Regenxbio
RGNX
$590M
$4.5M 1.4%
+204,494
New +$5.22M
GBT
20
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.9M 1.21%
+92,399
New +$4.36M
BMY icon
21
CALL
Bristol-Myers Squibb
BMY
$136B
$2.59M 0.8%
+7,500
New +$476K
LPCN icon
22
Lipocine
LPCN
$20.2M
$2.51M 0.78%
12,500
+186
+2% +$43K
IVTY
23
DELISTED
Invuity, Inc
IVTY
$2.45M 0.76%
175,000
+10,000
+6% +$131K
DYAX
24
DELISTED
DYAX CORPORATION
DYAX
$2.2M 0.68%
115,358
-443,783
-79% -$10.6M
LENS
25
DELISTED
Presbia PLC Ordinary Shares
LENS
$1.92M 0.6%
350,000
– –
1
2

Similar funds

CIM
Centersquare Investment Management Conshohocken, Pennsylvania $11.7B AUM 20.39% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
UE
Unisphere Establishment Vaduz, Liechtenstein $11.7B AUM 0.31% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $11.8B AUM 39.43% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

RTW Investments's Q3 2015 Portfolio in Review

As of Q3 2015, RTW Investments held 50 positions worth $322M, down 6.3% from $344M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

RTW Investments deployed $84.8M of net new capital in Q3 2015, opening 17 new positions and adding to 16 existing holdings. Its largest new stake was Mirati Therapeutics, Inc. Common Stock: 482,069 shares worth $16.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 84% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was DYAX CORPORATION, an estimated $10.6M trimmed.

  • RTW Investments's largest Q3 2015 buy was Mirati Therapeutics, Inc. Common Stock: 482,069 shares worth $16.6M.
  • RTW Investments added most to La Jolla Pharmaceutical Company in Q3 2015, an estimated $25.1M increase.
  • RTW Investments's biggest Q3 2015 reduction was DYAX CORPORATION, cutting an estimated $10.6M.
  • RTW Investments fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $3.88M.
  • RTW Investments's ten largest holdings make up 71% of its $322M portfolio in Q3 2015.
  • RTW Investments opened 17 new positions and closed 5 in Q3 2015.
  • RTW Investments's portfolio value fell 6.3% quarter-over-quarter to $322M.

Based on RTW Investments's 13F filing for Q3 2015, filed 13 Nov 2015.